Insider · SEC Form 4 filer
Felix Baker
Past buys: 3 of 3 beat
Companies
Where they file as an insider
Incyte (INCY) Director, 10% owner Latest filing Jun 30, 2026
Bicycle Therapeutics (BCYC) Director, 10% owner Latest filing Jan 2, 2026
Kymera Therapeutics (KYMR) Director, 10% owner Latest filing Dec 11, 2025
Entrada Therapeutics (TRDA) 10% owner Latest filing Nov 20, 2025
Madrigal Pharmaceuticals (MDGL) Director Latest filing Aug 18, 2025
KALA BIO (KALA) 10% owner Latest filing Dec 30, 2024
IGM Biosciences (IGMS) Director Latest filing Sep 29, 2023
Track record
Did their buys beat the typical stock?
Open-market buys60
Quarters checked 6 months later3
Beat the typical stock 3 of 3
Quarters too new to check0
3 of 3 checked quarters beat the typical stock. A past record is data, not a forecast.
Kymera Therapeutics (KYMR) Bought Dec 11, 2025 · $172M · 2.01M shares Beat typical Dec 31, 2025 $77.81 → Jun 30, 2026 $114.67 · +47.4% (typical stock +4.7%)
Madrigal Pharmaceuticals (MDGL) Bought Aug 18, 2025 · $25M · 68,618 shares Beat typical Sep 30, 2025 $458.66 → Mar 31, 2026 $523.47 · +14.1% (typical stock −3.4%)
Madrigal Pharmaceuticals (MDGL) Bought Nov 13–14, 2023 · $15.8M · 107,499 shares Beat typical Dec 31, 2023 $231.38 → Jun 30, 2024 $280.16 · +21.1% (typical stock −1.2%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.